Rhenman & Partners Asset Management AB Acquires New Shares in United Therapeutics Corporation $UTHR

Rhenman & Partners Asset Management AB bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,000 shares of the biotechnology company’s stock, valued at approximately $3,354,000.

A number of other hedge funds have also made changes to their positions in the company. Grantham Mayo Van Otterloo & Co. LLC raised its stake in shares of United Therapeutics by 67.6% during the 3rd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 15,068 shares of the biotechnology company’s stock worth $6,317,000 after buying an additional 6,079 shares during the last quarter. Orion Porfolio Solutions LLC grew its stake in United Therapeutics by 20.4% in the 3rd quarter. Orion Porfolio Solutions LLC now owns 4,225 shares of the biotechnology company’s stock valued at $1,771,000 after acquiring an additional 715 shares during the last quarter. Reyes Financial Architecture Inc. increased its holdings in United Therapeutics by 57.5% during the 3rd quarter. Reyes Financial Architecture Inc. now owns 389 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 142 shares in the last quarter. Cambria Investment Management L.P. increased its holdings in United Therapeutics by 5.0% during the 3rd quarter. Cambria Investment Management L.P. now owns 2,306 shares of the biotechnology company’s stock valued at $967,000 after acquiring an additional 109 shares in the last quarter. Finally, Legato Capital Management LLC raised its position in United Therapeutics by 33.0% during the third quarter. Legato Capital Management LLC now owns 6,522 shares of the biotechnology company’s stock worth $2,734,000 after acquiring an additional 1,618 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell?side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid?range price target, supporting a constructive medium?term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near?term weakness even if insiders retain stakes. Read More. Read More.

Insider Activity at United Therapeutics

In related news, Director Ray Kurzweil sold 4,910 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $489.02, for a total value of $2,401,088.20. Following the transaction, the director owned 12,670 shares in the company, valued at approximately $6,195,883.40. This trade represents a 27.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total value of $4,654,145.00. Following the transaction, the chief executive officer directly owned 130 shares in the company, valued at $63,688.30. This trade represents a 98.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 377,184 shares of company stock valued at $183,015,947 over the last three months. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 1.4%

Shares of United Therapeutics stock opened at $478.16 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $537.19. The business’s fifty day moving average is $482.51 and its two-hundred day moving average is $453.25. The firm has a market cap of $20.96 billion, a PE ratio of 17.14, a P/E/G ratio of 1.72 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.19 earnings per share. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the topic of several recent research reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. UBS Group lifted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday. HC Wainwright upped their target price on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company increased their target price on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Finally, Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $539.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.